{"id":139794,"date":"2026-10-02T16:19:11","date_gmt":"2026-10-02T16:19:11","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/139794\/"},"modified":"2026-10-02T16:19:11","modified_gmt":"2026-10-02T16:19:11","slug":"novartis-bets-up-to-7-8b-on-abogens-mrna-autoimmune-therapy","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/139794\/","title":{"rendered":"Novartis bets up to $7.8B on Abogen\u2019s mRNA autoimmune therapy"},"content":{"rendered":"<p>Why it matters: The approach could offer a simpler way to target the B cells that drive some autoimmune diseases. It aims to achieve deep B-cell depletion without collecting and engineering patients\u2019 immune cells, as conventional CAR-T therapies require.<\/p>\n<p>The deal comes weeks after <a href=\"https:\/\/european-biotechnology.com\/latest-news\/novartis-three-deaths-put-car-t-expansion-into-autoimmune-diseases-on-hold\/\" rel=\"nofollow noopener\" target=\"_blank\">Novartis paused autoimmune trials of its CAR-T candidate<\/a> rapcabtagene autoleucel following three patient deaths. ABO2203 gives the Swiss company another approach to pursuing an immune \u201creset,\u201d although its early results cannot establish whether it will be safer.<\/p>\n<p>How it works: ABO2203 packages mRNA inside lipid nanoparticles. Once delivered, the mRNA instructs the patient\u2019s cells to produce a protein called a T-cell engager. That protein connects CD3 on T cells with CD19 on B cells, directing the T cells to kill the B cells. The underlying mechanism is already used in Amgen\u2019s blood cancer drug Blincyto, but Abogen\u2019s twist is to deliver the instructions for making the engager inside the body.<\/p>\n<p>Zoom in: A study published in Cell <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42759514\/\" rel=\"nofollow noopener\" target=\"_blank\">reported<\/a> results in three patients with treatment-resistant secondary immune thrombocytopenia, a condition involving immune-mediated destruction of platelets.<\/p>\n<p>ABO2203 rapidly depleted B cells in blood, with sustained depletion in bone marrow. Patients showed platelet recovery and reduced disease activity through six months of follow-up. Reported adverse events were Grade 1 or 2, with no cytokine release syndrome, a potentially serious inflammatory reaction commonly seen in CAR-T therapies.<\/p>\n<p>Also notable: The researchers suggest ABO2203 could be administered by subcutaneous injection in an outpatient setting without premedication or lymphodepletion \u2014 the chemotherapy used to reduce immune cells before many CAR-T treatments. Those features could make treatment easier to deliver. However, the proposed advantages still need confirmation in larger studies.<\/p>\n<p>The deal: Alongside ABO2203, Novartis gains exclusive options to license additional programs from Abogen\u2019s RNA platform. Abogen could receive up to $7.2 billion (\u20ac6.4 billion) in development, regulatory and commercial milestones if all program options are exercised and the relevant milestones are met, plus potential royalties.<\/p>\n<p>What to watch: ABO2203 is being studied in Phase 1 trials in autoimmune diseases and B-cell non-Hodgkin lymphoma. The next question is whether the B-cell depletion and platelet responses seen in three patients translate into durable benefits across larger groups while maintaining a manageable safety profile.<\/p>\n","protected":false},"excerpt":{"rendered":"Why it matters: The approach could offer a simpler way to target the B cells that drive some&hellip;\n","protected":false},"author":2,"featured_media":139795,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[14272,206],"class_list":["post-139794","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-licensing","tag-novartis"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117372227817246225","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/139794","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=139794"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/139794\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/139795"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=139794"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=139794"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=139794"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}